The transcription factors LF-A1 and LF-B1 are required for the cell-specific expression of the human a1-antitrypsin gene In hepatocytes. We report here the purification and preliminary characterization of LF-A1. This protein, purified to homogeneity from calf liver nuclei by site-specific DNA affinity chromatography and reverse-phase HPLC, has a molecular mass of 40 kDa. Binding sites of LF-A1 are present in the promoter regions of several genes expressed in the liver (a1-antitrypsin, apolipoproteins A1, B1, A4 and pyruvate kinase). Interestingly, the binding site of LF-A1 Is bipartite and consists of two short sequence motifs (consensus: TGGAC T / C T /C and TGGCCC) separated by a variable 'spacer' region. Insertion or deletion of 1 -4 nucleotides in the 'spacer' region of the site In the a1-antitrypsin promoter does not abolish DNA binding.
INTRODUCTION
The efficiency and specificity of eukaryotic gene transcription is determined primarily by the interplay between cts-acting DNA sequences and fra/w-acting proteins that recognise such DNA elements (see refs. 1 -2 for reviews). Several fra/ts-acting factors have been characterised (3) (4) (5) and some of these are involved in transcriptional activation of genes in a particular cell type (6) (7) (8) (9) (10) . A detailed genetic and biochemical analysis of these factors clearly constitutes an important step in understanding the molecular mechanisms by which tissue-specific transcriptional control is achieved.
The hepatocyte-specific expression of genes coding for the plasma proteins represents a convenient model to investigate tissue-specific gene transcription. It has been shown that sequences within 100-300 bp from the transcriptional start site of many genes of this type (e.g. albumin, retinol binding protein, haptoglobin, a\ antitrypsin (alAT), /3 fibrinogen) are generally sufficient for cell-specific expression (11 -15) . These promoter regions contain several c£y-acting elements organised in various combinations in different genes and contain binding sites for both liver-specific and ubiquitous factors, which in some cases bind to the same DNA region in a mutually exclusive manner (16) (17) (18) .
We have previously analysed the hepatocyte-specific regulation of the human alAT gene in more detail. In vivo, the region beteen -137 and -37 from the start of transcription is sufficient for the expression from both the homologous alAT and the heterologous SV40 promoters (15) . Within this region, two functional domains have been identified by mutational analysis: the A-domain (-125 to -100) and the B-domain (-80 to -60), both of which are required for expression in hepatoma cells (15) . The A-and B-domains bind to the /ra/w-acting factors LF-A1 (also referred to as HNF2) and LF-B1 (also called HNF1) respectively (7, 8, 15, 18) . In addition, in vitro transcription experiments have also demonstrated that both LF-A1 and LFBl act as transcriptional activators (19) .
Recognition sequences for both LF-A1 and LF-B1 have been identified in the promoter regions of a large number of liver specific genes. For example, binding sites for LF-B1, which are conserved amongst several species (20) (21) , are present in albumin (11, 16, 17, 21) , a-fetoprotein (14, 22) , a-and 0-fibrinogen (14) , transthyreitin (23) and pyruvate kinase (24) whilst potential LF-A1 sites are present in apolipoproteins Al, AH and Bl (18, (25) (26) , haptoglobin (18) and pyruvate kinase (24) . In the case of a 1 AT and pyruvate kinase, both LF-A1 and LF-B1 are required for cell-specific expression (15, 24) suggesting some form of interaction between these two proteins. However, the promoters of apolipoprotein Al, apolipoprotein Bl and haptoglobin do not contain any LF-B1 binding sites. Since oligonucleotides containing the LF-A1 site, as present in the alAT promoter, can confer tissue-specific in vitro transcriptional activation on a heterologous promoter, it is likely that LF-A1 also acts as a positive transcription factor which is required for the expression of a set of specific genes in hepatocytes.
To further understand the role of both LF-A1 and LF-B1 in hepatocyte-specific gene expression, we have previously described the cloning and partial characterisation of the LF-B1 gene (7) . Here we report the purification of LF-A1 and show that it binds to a bipartite region in the regulatory regions of a large family of genes which are expressed in the liver.
MATERIALS AND METHODS

Purification of LF-A1
Nuclear extracts were prepared from calf liver essentially as described by Frain et al. (7) with minor modifications. All operations were performed at 0-4°C. Minced tissue (800 g liver) was brought to 1000 ml with buffer A (10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonylflouride (PMSF), 14 /ig/ml aprotinin, 3 /tg/ml pepstatin and leupeptin, 2 mM benzamidine, 0.15 mM spermine, 0.5 mM spermidine, 0.35 M sucrose) and homogenized in a motor-driven Potter homogenizer (10-15 strokes, 1400 rpm) until 90% cell lysis occurred. The homogenate was filtered through a cheesecloth and centrifuged at 4000 rpm for 25 min in a Beckman J-6B. The combined nuclear pellets were resuspended in 1000 ml of buffer A using the Teflon-glass Potter homogenizer (1 stroke, 800 rpm), layered over two 300 ml cushions of buffer B (buffer A containing 0.5M sucrose) and centrifuged as above. The nuclear pellet was then resuspended in 500 ml of buffer C (buffer A without sucrose) and centrifuged at 10,000 rpm for 20 min in a GSA rotor. The packed nuclei were resuspended in 3 volumes of buffer D (20 mM Hepes, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 14 /tg/ml aprotinin, 3 /tg/ml pepstatin and leupeptin, 5 mM benzamidine, 10% glycerol) using the Teflon-glass homogeniser (10 strokes, 800 rpm), stirred gently for 45 min and centrifuged at 10,000 rpm for 15 min in a GSA rotor. Ammonium sulphate was then added to the supernatant to 40% saturation (243 g in 1000 ml), stirred gently for 30 min and centrifuged at 10,000 rpm for 30 min in a GSA rotor. The pellet was frozen in liquid nitrogen and stored at -80°C. For some experiments, nuclear extracts were also prepared from rat liver by the method of Gorski et al. (11) . The protein concentration was determined according to the method of Bradford (27) . We usually obtained an average of 5 mg protein (in the form of the ammonium sulphate pellet) per gram of liver.
Major losses of LF-A1 activity occur due to precipitation during dialysis or dilution between chromatographic steps. However, the losses observed with dilution are slightly lower compared to dialysis. Thus, the ammonium sulphate pellet (3 g protein) was diluted with buffer D (20 mM Hepes, pH 7.9, 10% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 2 mM benzamidine and 0.1% Triton X100) to 2OO mM salt concentration and applied to a 200 ml DEAE-Sepharose CL-6B column equilibrated with buffer D containing 200 mM KCl. The flow-through, containing LFAl, was then loaded onto a 120 ml heparin-Sepharose CL-6B column equilibrated with buffer D containing 200 mM KCl. The column was then eluted with a linear gradient of KCl (200 mM to 600 mM) in buffer D. The LF-A1 activity eluting at 500-550 mM was pooled, diluted with buffer T (20 mM Tris, pH 7.2, 10% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 2 mM benzamidine and 0.1 % Triton X100) to 150 mM KCl and applied successively to 5 ml DNA-affinity columns. These were prepared by coupling multimers of APOB1 oligonucleotide (see below) to CNBr-activated Sepharose CL-4B as described by Kadonaga and Tjian (28) . The concentration of competitor DNA used in the purification was 30 /tg, 5 /ig and 3 /tg of sonicated salmon sperm DNA per ml for the first, second and third passes respectively. The column was washed successively with 5 vol of buffer T containing 150 and 200 mM KCl respectively and eluted with a 50 ml linear gradient of KCl (200-1000 mM). In some cases, LF-A1 was further purified by C8 reverse phase HPLC (2.1X30 mm columns from Applied Biosystems) at 40°C.
The columns were equilibrated with 5 % acetonitrile in 0.1 % triflouroaceticacid (TFA). After application of the proteins, the column was eluted at 0.1 ml/min with a linear gradient of acetonitrile (5-60%) in 0.1% TFA.
End-labelled DNA probes
The sequences of the coding strand of the oligonucleotides used are shown below and in Table 2 
DNA-binding assays
Gel retardation assays with purified protein were performed in a 20 /tl reaction volume containing 20 mM Tris, pH 7.6, 8% ficoll, 50 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 1 /tg poly (dl-dC) and 20 /tg bovine serum albumin (BSA). For crude nuclear extracts, 3 /tg of poly (dl-dC) was used and BSA was omitted. After 10 min on ice, 40,000 c.p.m. of end-labelled double-stranded oligonucleotide was added and the incubation continued for 15 min at room temperature. Free DNA and DNAprotein complexes were resolved on a 6% polyacrylamide gel in 0.25XTBE (45 mM Tris-borate, 45 mM boric acid and 2 mM EDTA). After the run the gel was dried onto DE52 paper and autoradiographed.
Preparative bandshift was performed essentially as described by Rupp and Sippel (30) . Radioactive APOB1 oligonucleotide (400,000 c.p.m.) was mixed with 40 pmol of unlabelled oligonucleotide and incubated with 20 /tl of affinity purified protein in a total of 60 /tl binding buffer containing 7.5 /tg poly (dl-dC). In control samples, either the oligonucleotide or protein was omitted. The samples were incubated at room temperature for 15 min and resolved on a 6% polyacrylamide gel. After the run, the gel was exposed wet at 4°C for 2 h and the gel slices containing the shifted band together with the adjacent region of the control lanes were excised and applied on the stacking gel of a 12.5% SDS-polyacrylamide gel. After electrophoresis, the proteins were visualised by staining with silver nitrate.
DNAase I footprint assays Protein fractions were preincubated in a 25 /tl reaction volume containing 25 mM Hepes, pH 7.9, 1 mM DTT, 20% glycerol, 0.1 % NP40 and 1 /tg poly (dl-dQ. After 10 min on ice, 8,000 c.p.m. end-labelled probe (in 25 /tl of 4% polyvinylalcohol) was added and the incubation continued for 15 min on ice. Then, 1 /tl of DNAase I, freshly diluted to a final concentration of 0.2-20 /tg/ml in 5 mM CaCl 2 and 10 mM MgCl 2 , was added and the digestion allowed to proceed for 1 min at room temperature. The digestion was stopped by adding 90 y\ of stop solution (20 mM EDTA, 1 % SDS, 0.2 M NaCl and 250 /xg/ml yeast tRNA). The DNA was extracted twice with phenol/chloroform, precipitated with 2.5 vol. ethanol, resuspended in 80% formamide and electrophoresed on a 6% polyacrylamide/7M urea gel.
Methylation interference assays Protein fractions were incubated under similar conditions as for gel retardation assays except that a large amount of partially methylated probe (31; 400,000 c.p.m.) was added. Both the free DNA and the DNA-protein complex were excised from the gel and the DNA was eluted overnight in TE8 buffer. The DNA was loaded onto a 0.1 ml DE52 column and eluted with 700 /tl of 1.5 M ammonium acetate. After adding 3 /tg of tRNA, the DNA was extracted twice with phenol/chloroform, precipitated with ethanol, treated with 10% piperidine for 30 min at 90°C, dried and electrophoresed on a 6% polyacrylamide/7M urea gel.
RESULTS
Several proteins recognise LF-A1 binding sites
Recognition sequences for LF-A1 have been identified in the promoter regions of many genes expressed in the liver (e.g. alAT, APOA1, APOB1; [18] [19] 26) . In the case of the alAT promoter, we have shown that binding of LF-A1 is required.for transcriptional activity since the EM3 and EM4 mutations which l-3-1 abolish transcription in hepatoma cells also abolish DNA binding (18) . In order to investigate whether the same protein in crude nuclear extracts also binds to the sites in the promoter of APOA1 and APOB1, we synthesised oligonucleotides corresponding to these sites (see Materials and Methods) and used them in a gel retardation assay with extracts from rat liver, spleen and brain. As shown in Figure \ , only a single DNA-protein complex can be observed with the al AT site using nuclear extracts from liver (lane 1), which is absent in spleen (lane 2) and probably present at low levels in brain Qane 3), although this may represent a complex from a related protein. At least three complexes can be detected with liver extracts using the site from the promoter of APOA1 whilst two retarded bands are obtained with the site from APOB1 (Figure 1, lanes 4 and 7) suggesting that a family of LF-Al-like proteins probably exists. Only one of these (complex 1 in Figure 1 ) represents LF-A1 since it is absent in spleen and brain (data not shown) and can be competed with a 100-fold molar excess of unlabelled oligonucleotide containing the alAT site but not with an unrelated oligo ( Figure 1 , lanes 5-6, 8-9). We thus decided to purify this protein from liver nuclei.
Purification of LF-A1
LF-A1 is present at very low levels in both hepatoma cells or tissues. In addition, large losses of its activity occur during chromatographic steps due to its tendency to precipitate upon dilution. The protein was thus purified from calf liver in order to obtain sufficient quantities for sequencing and biochemical analysis. For the purification, crude nuclear extracts were precipitated with 40% ammonium sulphate and passed over a DEAE-Sepharose column to remove contaminating nucleic acids. No detectable LF-A1 activity, as judged by mobility-shift assays using APOB1 oligonucleotide, remained on the column . Gel retardation analysis with crude nuclear extracts. Bandshift assays were performed with oligonucleotides corresponding to the LF-A1 binding sites from the promoter of a 1 AT (lanes 1-3), APOA1 (lanes 4-6) and APOB1 (lanes 7-9). Nuclear extracts from rat liver were used for all the experiments except with lanes 2 (spleen) and 3 (brain). For competition experiments, nuclear extracts (3 pig) were preincubated with either specific competitor (the al AT oligo; lanes 5 and 8) or a non speciiic competitor (lanes 6 and 9). After addition of radiolabelled APOA1 (lanes 5-6) or APOB1 (lanes 8-9) oligonucleotides, the free DNA and the DNA-protein complex were separated on a 6% polyacrylamide gel. The sequences of the oligonucleotides used are shown in Materials and Methods. under the conditions used. The flow-thorough from DEAE-Sepharose was fractionated on a heparin-Sepharose column. The majority of nuclear proteinsi were present in the excluded volume of the column whilst LF-A1 activity eluted between 500-550 mM KC1. Active fractions were pooled, mixed with nonspecific competitor DNA, and fractionated further by repeated chromatography over a DNA affinity column comprising concatenated synthetic APOB1 oligonucleotides coupled to Sepharose 4B. The final overall yield of LF-A1 could not be determined because of contaminating activities in the crude nuclear extracts or diluted ammonium sulphate pellet which strongly interfered with binding. However, the 2nd affinity pool was purified approximately 20,000 fold with respect to the heparin-Sepharose pool. The purification obtained in various steps was thus evaluated by SDS polyacrylamide gel electrophoresis followed by silver staining (Figure 2A and Figure 3 , lane 1). Several proteins can be observed after three cycles of DNA affinity chromatography ( Figure 3 , lane 1) although three polypeptides with the approximate molecular mass of 40, 32 and 26 kDa form the predominant species. Attempts to identify the band representing LF-A1 by renaturing the proteins after separation on SDS polyacrylamide gel electrophoresis failed. This inability to renature LF-A1 is due to some specific property of this factor rather than the procedure used because several low molecular weight proteins present in the material renatured very efficiently. However, the interaction of these proteins was not specific for the LF-A1 binding site. As a result, the preparative bandshift (30) was used to identify LF-A1. For this, the DNA-protein complex was fractionated on a native polyacrylamide gel, together with control samples without DNA or proteins. The region of the gel containing the specific DNA-protein complex and the corresponding regions of the control lanes were excised and applied on an SDS polyacrylamide gel. As shown in Figure 3 , the polypeptide with the molecular mass of 40 kDa contains the 2 The positions of the EM3 and EM4 mutations in the alAT promoter is underlined whilst methylation of G residues which affect binding on the coding and non-coding strands are shown by the symbols * and • respectively. Blank spaces in the sequences indicate spaces inserted to improve the alignment of putative consensus sites. LF-A1 binding activity. This species can be purified to homogeneity by reverse-phase HPLC ( Figure 2B, lane 1) . However, the HPLC purified protein does not bind to DNA because the protein denatures during this purification step and LF-A1 cannot be renatured upon denaturation. We usually obtained between 2-3 /ig protein per gram of nuclear extracts.
LF-A1 interacts with a family of hepatic genes
As described earlier, potential binding sites for LF-A1 have been identified in the promoter regions of several genes expressed in the liver (18) (19) (24) (25) (26) . However, these studies used either crude nuclear extracts or partially purified LF-A1. In order to ascertain whether the protein we have purified also interacts with these regions, we synthesised oligonucleotides corresponding to some of these putitive recognition sequences and used them in a gel retardation assay with purified protein from calf liver. As shown in Figure 4 , binding sites of LF-A1 are present in the promoter of the genes for alAT, APOA1, APOB1, APOA4 and pyruvate kinase. This binding is specific for LF-A1 and not due to any non-specific interactions or contaminating activities since it can be competed with a 100-fold molar excess of unlabelled specific oligonucleotide (the binding site from the alAT promoter which only binds LF-A1; Figure 1 ) but not by a non-related double stranded oligonucleotide (Figure 4) . Similar results were also obtained using LF r Al purified from rat liver (data not shown). In addition, calf LF-A1 does not bind to an oligonucleotide containing the EM3 mutation ( Figure 4 , lane 16), which abolishes both the transcription of the alAT gene in vivo (15) and binding to rat liver LF-A1 (18) , suggesting that both the calf and rat LF-A1 have similar binding specificity. In the case of the APOB1 promoter, we also determined the exact binding site of LF-A1 by DNAase I footprinting (31) and methylation interference (32) experiments. Figure 5A shows that the region which is protected against DNAase I digestion extends from -56 to -83 on the coding strand and -60 to -86 on the non-coding strand, with DNAase I hypersensitivity at -75 and Table 2 . F indicates free DNA, C shows DNA-protein complex. The asterisks indicate extra bands which are due to partial denaturau'on of the probe during ethanol precipitation (37) . The presence of this band does not affect binding of LF-Al.
-79 respectively. Within this region methylation of the guanine residues at positions -70, -71 and -78 of the coding strand and -68, -75 and -76 of the non-coding strand abolishes binding ( Figure 5B) . A schematic representation of the DNAase I and methylation interference data is given in Figure 5C . These results are in agreement with those obtained using crude nuclear extracts (26) .
The LF-Al binding site contains two short motifs Table 1 compares the binding site of LF-Al in the promoter regions of several genes expressed in the liver. The position of die EM3 and EM4 mutants of the alAT promoter, which affects bodi the binding of LF-Al and transcription in vivo (15, 18) , are underlined. In addition, the bases whose methylation interferes with LF-Al binding are also shown. There is no evidence for a palindromic structure of the recognition sequence in any of these sites. A consensus TGGAAC T / C T / C can be deduced for the distal part of the binding site (defined by the EM3 mutant). However, when these sequences are displayed colinearly no obvious homology can be found between the proximal part of the sites (defined by the EM4 mutation; data not shown). Introduction of a gap of 1 to 4 bases at an arbitrary position shortly after the putitive proximal unit does allow the alignment of identical bases in the distal part of the site (Table 1) . It is therefore likely that the LF-Al site may be bipartite and consist of two short sequence elements with a variable spacing. To investigate this possibility, mutant oligonucleotides corresponding to the alAT site in which the 'spacer' region was altered (Table  2) were analysed for binding to affinity purified LF-Al. As shown in Figure 6A , deletion of a single base or insertion of 1 -4 nucleotides in the 'spacer' region does not abolish DNA binding. In addition, half sites containing either the distal or proximal motifs do not bind the protein ( Figure 6B ). These data, in conjunction with the observation that the EM3 and EM4 mutations abolish DNA binding, strongly suggest that the LFAl binding site indeed consists of two short motifs separated by a variable 'spacer' region.
DISCUSSION
We have purified the transcription factor LF-Al to near homogeneity using a combination of heparin-Sepharose, sitespecific DNA affinity chromatography and reverse-phase HPLC. The remarkable efficiency of DNA affinity chromatography is illustrated by the observation that only a few polypeptide species can be detected after three cycles (Figure 3, lane 1) . We routinely observed these polypeptides in every preparation even when die protein was purified from rat liver or subjected to further rounds of affinity chromatography. Preparative bandshift analysis showed that the polypeptide with molecular mass of 40 kDa represents LF-Al (Figure 3 ). This polypeptide species can be purified to homogeneity by reverse-phase HPLC ( Figure 2B, lane 1) . However, we have currently not determined whether the purified protein is intact and can activate transcription in non-hepatic tissues as shown for HNF1 (37) or whether it only represents the DNA-binding domain.
Purified LF-A1 interacts with the promoter regions of several genes expressed in hepatocytes (Figure 4) . In almost every case where functional data is available, the LF-Al binding site is localised in an essential promoter region. For example, mutation of die LF-Al binding site in both the alAT and pyruvate kinase promoters drastically affects transcription of these genes (15, 24) In addition, Kardassis et al. (26) have shown that mutation in the -77 to -68 region of the APOB1 promoter [overlapping witii the LF-Al binding site ( Figure 5 )] abolishes transcription of die promoter-CAT fusion gene in hepatocytes. Similarly sequences between -235 and -190 of die APOA1 gene promoter, containing an LF-Al site, are not only essential but sufficient for transcription in hepatoma cells (38) . Furthermore, Monaci et al. (19) have shown that the LF-Al site in the alAT gene can confer liver-specific transcription when cloned in either orientation in front of a truncated HSV thymidine kinase promoter. Finally, although no functional information is available concerning die LF-Al sites in die promoters of APOA4 and haptoglobin, tiieir positions, -120 and -82 bp respectively, strongly suggests tiiat they may be involved in the transcription of these genes since sequences within 100-300 bp from die transcriptional start sites of several genes expressed in hepatocytes are sufficient for dieir cell-specific expression (11 -15) .
It is interesting to note that LF-Al binding sites are present in die 5' flanking regions of at least four apolipoprotein genes (APO Al, AH, Bl and A4) and, therefore, may be involved in die coordinate regulation of gene expression. The apolipoproteins play an important role in lipid transport and metabolism. Their genes are not exclusively expressed in die liver. For example, the APOA1 and APOA4 genes are expressed more strongly in the intestine (34, 35) . In the case of APOA1 and APOA4, it is not known whether die same promoter elements are required for the expression of die genes in different tissues. However, mutation in die -77 to -68 region of the APOB1 promoter, containing an LF-Al binding site, abolishes transcription of die promoter-CAT fusion gene in botii hepatocytes and intestine (26) . It will be interesting to determine whether die same factor binds to diis region in both tissues. We have been unable to detect LF-Al in nuclear extracts from rat kidney, rat spleen or HeLa cells (Figure 1 ; otiier data not shown). In addition, LF-Al binding sites can only stimulate in vitro transcription from a heterologous promoter in extracts from rat liver but not spleen (19) suggesting that LF-A1 is liver specific.
The LF-A1 binding site is bipartite and consists of two short sequence motifs (consensus: JGGAC^I^IQ and TGGCCC) separated by a variable 'spacer' region (Table 1) . Mutations in either of these motifs in the promoter of the alAT gene (the EM3 and EM4 mutants) severely impair binding and transcription activity (15) . The binding site in the promoters of haptoglobin and haptoglobin related gene deviates strongly from the consensus and is consistent with its low affinity for LF-A1. Interestingly, the 'spacer' region is dispensible since deletion of 1 bp or insertion of 1 -4 bp in the 'spacer' of the alAT does not abolish DNA binding (Figure 6 ). It is currently not known whether LFAl binds to its recognition site as a monomer or as a dimer. The two motifs of the LF-A 1 binding site are quite close to direct repeats of each other suggesting that the protein may bind to DNA as an asymmetrical dimer. However, the molecular weight of LF-A1 determined by either SDS polyacrylamide gel electrophoresis or gel filtration chromatography are identical suggesting that the protein exists in solution as a monomer (data not shown). If LF-A1 binds as a monomer, then it is difficult to explain how a DNA binding domain on a single polypeptide can accommodate for the variable spacing. One possibility is that LF-A1 may contain a rather unconventional structure consisting of two hinged DNA binding domains on a single polypeptide.
Recently Rangan and Das (39) described the purification of a nuclear protein from rat liver which they presume to be HNF2. However, this protein differs from the LF-A1 we have purified in the relative molecular mass (68 kDa for HNF2 and 40 kDa for LFA1), ability to bind to a MonoQ column at 50 mM KC1 (HNF2 is retained whilst LF-A1 is excluded) and their ability to renature upon denaturation (HNF2 can whilst LF-A1 cannot). These differences are not due to species variation since the rat and calf LF-A 1 display similar properties. HNF2 was shown only to bind to the alAT promoter (39) . We have observed that several proteins from either rat or calf liver bind to a subset of LF-A1 binding sites from the promoter regions of different genes. For example, oligonucleotides from the -130 to -94 region of the alAT promoter, containing an LF-A1 binding site, binds to at least four activities (data not shown) whilst several distinct activities, including LF-A1, bind to the APOA1 and APOB1 oligonucleotides (Figure 1 ). In the case of APOA1, we have partially purified one of these related proteins. Similar to LFAl, this protein also loses activity upon heating at 65°C for 5 min and generates an identical footprint on the APOA1 promoter (Papazafiri et al., manuscript submitted for publication). This suggests that similar to the octamer transcription factor (see ref.
40 for a review), a family of LF-Al-like proteins may exist. Interestingly, the human transferrin gene promoter also contains sequences homologous to LF-A1 binding sites but they bind proteins distinct from LF-A1 (referred to as TfLFl and TfLF2; 41). Therefore, in order to ensure that the protein we are purifying is LF-A1 and not one of these related proteins, we routinely check preparations for loss of activity upon heating at 65°C for 5 mih and binding to oligonucleotides representing several different binding sites and to the alAT site containing the EM3 mutation (Figure 4) . The shortest segment which is able to direct correct expression of any liver-specific promoter analysed to date contains recognition sequences for a number of factors. For example, six factors bind to the mouse albumin promoter (11, 16-17) whilst five different proteins bind to the promoter of human al AT (LFAl, LF-A2, LF-B1, LF-B2, LF-C; 19 ). This suggests that the specificity and efficiency of liver-specific gene transcription depends on the interactions of cell-specific, ubiquitous and general transcription factors. Analysis of several genes expressed in hepatocytes has indicated that at least three nuclear proteins play a crucial role in the positive, cell-specific regulation of gene expression: LF-A1, LF-B1 and C/EBP. The genes coding for LF-B1 and C/EBP have recently been cloned and their DNA binding domains mapped (7, 8, 42, 43) . A detailed analysis of the mechanisms responsible for liver-specific gene transcription clearly requires the cloning of the LF-A1 gene. The purification of LF-A1, described in this report, is an important step towards this goal.
